154 related articles for article (PubMed ID: 30816914)
1. Tumour necrosis factor superfamily members in ischaemic vascular diseases.
Nash M; McGrath JP; Cartland SP; Patel S; Kavurma MM
Cardiovasc Res; 2019 Mar; 115(4):713-720. PubMed ID: 30816914
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.
Ślebioda TJ; Kmieć Z
Mediators Inflamm; 2014; 2014():325129. PubMed ID: 25045210
[TBL] [Abstract][Full Text] [Related]
3. Considering TWEAK as a target for therapy in renal and vascular injury.
Ortiz A; Sanz AB; Muñoz García B; Moreno JA; Sánchez Niño MD; Martín-Ventura JL; Egido J; Blanco-Colio LM
Cytokine Growth Factor Rev; 2009 Jun; 20(3):251-8. PubMed ID: 19482507
[TBL] [Abstract][Full Text] [Related]
4. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.
Croft M; Siegel RM
Nat Rev Rheumatol; 2017 Apr; 13(4):217-233. PubMed ID: 28275260
[TBL] [Abstract][Full Text] [Related]
5. Role of the TWEAK/Fn14 pathway in autoimmune diseases.
Xu WD; Zhao Y; Liu Y
Immunol Res; 2016 Feb; 64(1):44-50. PubMed ID: 26659091
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor superfamily ligand mRNA expression profiles differ between humans and mice during homeostasis and between various murine kidney injuries.
Devarapu SK; Grill JF; Xie J; Weidenbusch M; Honarpisheh M; Vielhauer V; Anders HJ; Mulay SR
J Biomed Sci; 2017 Sep; 24(1):77. PubMed ID: 28927419
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor superfamily molecules in acute coronary syndromes.
Aukrust P; Sandberg WJ; Otterdal K; Vinge LE; Gullestad L; Yndestad A; Halvorsen B; Ueland T
Ann Med; 2011 Mar; 43(2):90-103. PubMed ID: 21039303
[TBL] [Abstract][Full Text] [Related]
8. Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface.
Lee WH; Seo D; Lim SG; Suk K
Front Immunol; 2019; 10():262. PubMed ID: 30838001
[TBL] [Abstract][Full Text] [Related]
9. In Development-A New Paradigm for Understanding Vascular Disease.
Flavahan NA
J Cardiovasc Pharmacol; 2017 May; 69(5):248-263. PubMed ID: 28328747
[TBL] [Abstract][Full Text] [Related]
10. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity.
Campbell S; Michaelson J; Burkly L; Putterman C
Front Biosci; 2004 Sep; 9():2273-84. PubMed ID: 15353286
[TBL] [Abstract][Full Text] [Related]
11. The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond.
Dostert C; Grusdat M; Letellier E; Brenner D
Physiol Rev; 2019 Jan; 99(1):115-160. PubMed ID: 30354964
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the expression patterns of various TNFSF/TNFRSF in atherosclerotic plaques.
Kim WJ; Kang YJ; Suk K; Park JE; Kwon BS; Lee WH
Immunol Invest; 2008; 37(4):359-73. PubMed ID: 18569075
[TBL] [Abstract][Full Text] [Related]
13. Tweak and FN14 in central nervous system health and disease.
Yepes M
Front Biosci; 2007 May; 12():2772-81. PubMed ID: 17485258
[TBL] [Abstract][Full Text] [Related]
14. TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes.
Salzmann S; Lang I; Rosenthal A; Schäfer V; Weisenberger D; Carmona Arana JA; Trebing J; Siegmund D; Neumann M; Wajant H
J Immunol; 2013 Sep; 191(5):2308-18. PubMed ID: 23918987
[TBL] [Abstract][Full Text] [Related]
15. TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
Bernardi S; Voltan R; Rimondi E; Melloni E; Milani D; Cervellati C; Gemmati D; Celeghini C; Secchiero P; Zauli G; Tisato V
Clin Sci (Lond); 2019 May; 133(10):1145-1166. PubMed ID: 31097613
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.
Hemmerle T; Hess C; Venetz D; Neri D
J Biotechnol; 2014 Feb; 172():73-6. PubMed ID: 24384233
[TBL] [Abstract][Full Text] [Related]
17. Structural insights of homotypic interaction domains in the ligand-receptor signal transduction of tumor necrosis factor (TNF).
Park YH; Jeong MS; Jang SB
BMB Rep; 2016 Mar; 49(3):159-66. PubMed ID: 26615973
[TBL] [Abstract][Full Text] [Related]
18. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
[TBL] [Abstract][Full Text] [Related]
19. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis.
Blanco-Colio LM; Martín-Ventura JL; Munoz-Garcia B; Moreno JA; Meilhac O; Ortiz A; Egido J
Front Biosci; 2007 May; 12():3648-55. PubMed ID: 17485328
[TBL] [Abstract][Full Text] [Related]
20. Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.
Prigozhina TB; Szafer F; Aronin A; Tzdaka K; Amsili S; Makdasi E; Shani N; Dranitzki Elhalel M
Cancer Lett; 2017 Aug; 400():99-109. PubMed ID: 28455246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
